Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Cash from Operations: 2020-2024

Historic Cash from Operations for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$158.6 million.

  • NewAmsterdam Pharma Co N.V's Cash from Operations fell 162.11% to -$32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.4 million, marking a year-over-year increase of 6.34%. This contributed to the annual value of -$158.6 million for FY2024, which is 12.28% down from last year.
  • According to the latest figures from FY2024, NewAmsterdam Pharma Co N.V's Cash from Operations is -$158.6 million, which was down 12.28% from -$141.2 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's 5-year Cash from Operations high stood at $10.7 million for FY2022, and its period low was -$158.6 million during FY2024.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Cash from Operations value was -$141.2 million (recorded in 2023), while the average stood at -$96.4 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Cash from Operations skyrocketed by 136.14% in 2022 and then tumbled by 1,424.13% in 2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Cash from Operations (Yearly) stood at -$6.8 million in 2020, then slumped by 332.96% to -$29.5 million in 2021, then surged by 136.14% to $10.7 million in 2022, then tumbled by 1,424.13% to -$141.2 million in 2023, then decreased by 12.28% to -$158.6 million in 2024.